RHHBY - Your Daily Pharma Scoop: ResTORbio Progresses Roche Closer To Review AbbVie Falters
Stocks in News: TORC, RHHBY
ResTORbio's RTB101 shows treatment benefit in mid-stage study; shares up 9%
Discussion: ResTORbio (TORC) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infection-lowering ability. The datasets were published in Science Translational Medicine. The study showed that RTB101 both as monotherapy as well as in combination with Novartis’s Afinitor (everolimus), showed statistically significant reduced rate of respiratory tract infections.
The combination therapy also clearly enhanced the response to influenza vaccination and favourably